At Pathalys #Pharma our mission is to improve the lives of #patients through enhanced #therapeutics that will advance the management of #chronic #kidneydisease.
Location: United States, North Carolina, Raleigh
Employees: 1-10
Total raised: $255M
Founded date: 2021
Investors 3
| Date | Name | Website |
| 30.08.2023 | OrbiMed | orbimed.co... |
| 04.05.2022 | Catalys Pa... | catalyspac... |
| 04.04.2022 | DaVita Ven... | davitavent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.08.2024 | Series B | $105M | - |
| 20.01.2023 | - | $150M | - |
Mentions in press and media 12
| Date | Title | Description |
| 23.08.2024 | Pathalys Pharma's $105 Million Boost: A Leap Toward Kidney Disease Solutions | Pathalys Pharma is on the brink of a breakthrough. The North Carolina-based biopharmaceutical company recently secured $105 million in a Series B funding round. This significant financial injection aims to propel the development of upacical... |
| 23.08.2024 | The Week’s 10 Biggest Funding Rounds: Grafana Labs Raises $270M To Lead Slow Week | 4 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 23.08.2024 | Pathalys Pharma: $105 Million (Series B) Raised To Develop Treatments For Kidney Disease | Pathalys Pharma, a private biopharmaceutical company in the late stages of developing treatments for kidney disease, announced it closed a $105 million Series B funding round. This oversubscribed financing was led by TCGX and joined by othe... |
| 20.08.2024 | Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA | Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney-disease-focused biotech will use to take its lead candidate through the final stages of clinical development. The company’s primary focus is upacicalcet, a... |
| 20.08.2024 | Pathalys Pharma Raises $105M in Series B Funding | Pathalys Pharma, a Research Triangle Park, NC-based biopharmaceutical company in the late stages of developing treatments for kidney disease, raised $105M in Series B funding. The round was led by TCGX, which was joined by other investors i... |
| 30.01.2023 | 50 recently-funded startups to watch in 2023 | With the ongoing economic downturn and fear of a recession, tech startups have been hit hard as investors pulled back from new venture deals and reduce their investment in startups with exposure to recession. Further expounding on the fundi... |
| 20.01.2023 | The Week’s 10 Biggest Funding Rounds: Pathalys Pharma Lands $150M; Impel Drives Away With $104M | 21 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2023 with our new curated list of $100 million-plus venture deals to U.S.-based companies? Check out our new Megadeals Tracker here. This i... |
| 20.01.2023 | Pathalys Pharma Raises $150M in Secured Product Financing and Equity | Pathalys Pharma, a Raleigh, NC-based private, late-stage biopharma company, raised $150M in Secured Product financing and equity funding. Abingworth led both financings and was joined by Carlyle and OrbiMed, along with Pathalys’ founding in... |
| 18.01.2023 | Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Stu... | Research Triangle Park, North Carolina and Boston, Massachusetts, January 18, 2023 — Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx),... |
| 18.01.2023 | Pathalys Pharma Raises $150M | RESEARCH TRIANGLE PARK, NC, Pathalys Pharma, Inc., a private, late-stage biopharma company. >> Click here for more funding data on Pathalys Pharma >> To export Pathalys Pharma funding data to PDF and Excel, click here Pat... |
Show more